Authors' objectives:
The chimeric antigen receptor (CAR) T-cell therapies tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) are provisionally listed in Appendix 1 of the Health Insurance Benefits Ordinance in Switzerland until 31 December 2024 for the third-line treatment of B-cell acute lymphoblastic leukaemia (B-ALL), diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL). This health technology assessment (HTA) evaluates the available evidence regarding the efficacy, effectiveness, safety, costs, cost-effectiveness and budget impact of tisa-cel and axi-cel compared to standard care in these populations. Ethical, legal, social and organisational issues associated with these therapies are also explored.
CAR T cell therapies; CAR-T; tisagenlecleucel; Yescarta®; Kymriah®; diffuse large B cell lymphoma; lymphoma; B cell acute lymphocytic leukaemia; leukaemia; primary mediastinal B cell lymphoma; axicabtagene ciloleucel; PROMs; efficacy; effectiveness; safety; costs; economics; cost-effectiveness; budget impact; legal; social; ethical; organisational
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ; Antineoplastic Agents, Immunological ; Leukemia ; B-Cell ; Lymphoma ; Large B-Cell ; Diffuse ; Immunotherapy ; Adoptive ; Receptors ; Antigen ; T-Cell ; Leukemia ; Lymphocytic ; Chronic ; B-Cell ; Receptors ; Chimeric Antigen
Not Available
